Core Insights - Avalo Therapeutics has initiated the Phase 2 LOTUS trial for AVTX-009, a monoclonal antibody targeting interleukin-1β, in patients with hidradenitis suppurativa (HS) [1][2] - The trial aims to evaluate the efficacy and safety of two dosing regimens of AVTX-009 compared to placebo, with topline results expected in 2026 [1][2] Company Overview - Avalo Therapeutics is a clinical-stage biotechnology company focused on treating immune dysregulation, with AVTX-009 as its lead asset targeting inflammatory diseases [5] - The company also has two additional drug candidates: quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein) [5] Industry Context - Hidradenitis suppurativa is a chronic inflammatory skin condition that significantly impacts quality of life, with an estimated prevalence of 0.2-1.7% of the global population [3] - Current treatment options for HS are limited, and there is a need for improved therapies targeting the inflammatory processes, particularly those involving interleukin-1β [3][4]
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa